Our Drug Pipeline
We explore nature’s hidden bioactive compounds, refine their therapeutic potential, and advance the most promising candidates through each development stage. Our team works tirelessly to reduce complexity, accelerate discovery, and bring life-changing treatments one step closer to the patients who need them most.
Drug Development Pipeline
Pre-clinical
Target Disease:
Solid Tumor (DNA damage response deficient cancers)
Identity: NB-A001
Molecules/API/Key Status:
Small molecule - Lead compound
Stage: Pre-clinical
Pre-clinical
Target Disease:
Solid Tumor (DNA damage response deficient cancers)
Identity: NB-A002 (NYH002)
Molecules/API/Key Status:
Small molecule - NB-A001 derivative
Stage: Pre-clinical
In-vitro
Target Disease:
Solid Tumor (DNA damage response deficient cancers)
Identity: NB-A007
Molecules/API/Key Status:
Small molecule - NB-A001 derivative
Stage: In-vitro
Pre-clinical
Target Disease:
Solid Tumor (DNA damage response deficient cancers)
Identity: NB-B101
Molecules/API/Key Status:
Small molecule - Lead compound
Stage: Pre-clinical
Pre-clinical
Target Disease:
Solid Tumor (DNA damage response deficient cancers)
Identity: NB-B102
Molecules/API/Key Status:
Small molecule - NB-B101 derivative
Stage: Pre-clinical
In-vitro
Target Disease:
Solid Tumor (DNA damage response deficient cancers)
Identity: NB-B107
Molecules/API/Key Status:
Small molecule - NB-B101 derivative
Stage: In-vitro
In-vitro
Target Disease:
Metabolic Diseases
Identity: NB-C201
Molecules/API/Key Status:
Small molecule - Lead compound
Stage: In-vitro
In-vitro
Target Disease:
CVD
Identity: NB-H7
Molecules/API/Key Status:
Herb Identified, Extracting API
Stage: In-vitro
In-vitro
Target Disease:
Fatty Liver Diseases
Identity: NB-H2
Molecules/API/Key Status:
Herb Identified, Extracting API
Stage: In-vitro
In-vitro
Target Disease:
Obesity
Identity: NB-H5
Molecules/API/Key Status:
Herb Identified, Extracting API
Stage: In-vitro
Breakthrough Innovation
Revolutionizing Cancer Treatment: First-in-Class Small Molecules for HRD-Positive, Chemo-Resistant Cancers
Molecule: NB-A002 (NYH002)
Problem: HRD-positive cancers resist standard treatments like PARP inhibitors and platinum-based chemotherapy, leading to poor patient outcomes. New solutions are urgently needed.
Solution: NB-A002 (NYH002) – our novel molecules derived from tropical medicinal plants. Engineered to trigger synthetic lethality via Transcription-Replication Conflicts, they effectively target DNA damage response deficient cancers.
Featured news
No items found.
